GLP-1 weight loss claims on TikTok: what the data says
Quick answer
The creator discontinued semaglutide after approximately 45 to 50 pounds of weight loss and reports continued loss through the following 3 months, reaching 80 to 85 pounds total before becoming pregnant. This trajectory is atypical compared to post-discontinuation data from the STEP 1 Extension trial, where participants regained roughly two-thirds of lost weight within one year of stopping the medication. Her subsequent pregnancy adds a significant confounding variable that makes this experience difficult to generalize.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @ariasahota actually say?
She stopped Ozempic at the end of May after losing 45 to 50 pounds. Then, without the medication, she kept losing weight through August, reaching 80 to 85 pounds total lost. She got pregnant mid-August, shifted to maintenance, and says she has gained only "3 to 5 pounds" during the pregnancy so far. Her bottom line: stopping Ozempic did not cause rebound weight gain for her.
To her credit, she explicitly says "this may not be the case for every individual" in her caption. That caveat matters a lot here, and she deserves credit for including it. Her experience is real. Whether it reflects what most people can expect is a different question entirely.
Does the science back this up?
Not for most people. The dominant finding in the clinical literature is that weight regain after stopping semaglutide is common, substantial, and relatively fast. This is not a fringe result.
The STEP 1 Extension trial (Wilding et al., 2022, Diabetes, Obesity and Metabolism) followed participants for one year after stopping semaglutide. They regained about two-thirds of their lost weight within 12 months. Cardiovascular risk markers and blood sugar levels also trended back toward baseline. A separate analysis of the SUSTAIN and STEP program data consistently showed that the drug's appetite-suppressing effects diminish once the medication is discontinued.
So what might explain her continued loss? A few possibilities exist. She may have made substantial behavioral changes, dietary shifts, or increased physical activity during her time on the medication that she maintained afterward. Pregnancy-related changes in appetite and eating behavior are also real and variable. None of this makes her outcome impossible. It just makes it an outlier relative to the research population.
What did they get wrong (or right)?
She got the caveat right. Saying "this may not be the case for every individual" is accurate understatement. The science suggests rebound is the norm, not the exception.
What she implicitly gets wrong, probably without intending to, is the framing. A 2.4 million view video showing someone who stopped Ozempic and kept losing weight creates a meaningful impression, regardless of the disclaimer in the caption. Most viewers will not read that caveat. They will absorb the story: stopped the drug, still lost weight, no big deal.
That impression conflicts directly with what researchers observe. Wilding et al. 2022 is not an outlier study. It is one of the most cited post-discontinuation analyses available. The mechanism is also well understood: semaglutide suppresses appetite by acting on GLP-1 receptors in the brain. When the drug leaves the system, that suppression fades. Sustained weight loss after stopping requires the person to have independently rebuilt appetite regulation and behavior, which is possible but not typical.
She also does not mention that she is pregnant, which significantly complicates interpreting her weight trajectory as a clean post-Ozempic data point.
What should you actually know?
Stopping a GLP-1 medication is a real clinical decision with real consequences for most people. The Wilding 2022 data is clear: expect to regain a significant portion of lost weight unless you have built durable behavioral changes that function independently of the drug.
This does not mean GLP-1 medications are not worth taking. It means they work while you take them, and the question of long-term use versus discontinuation should involve a prescribing clinician who knows your full picture, not a TikTok comment section.
Some people do maintain weight loss after stopping. The behavioral psychology literature on habit formation and food environment restructuring suggests this is more likely when the medication period was used to build new patterns, not just reduce appetite passively. But that is a best-case scenario, not a baseline expectation.
Her pregnancy is also a relevant variable. Weight management goals during pregnancy are medically distinct from general weight loss. Gaining only 3 to 5 pounds into a pregnancy is not automatically a health achievement to replicate. Anyone who is pregnant should be working with an OB or midwife on appropriate weight goals, which vary by starting BMI and other factors.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 weight loss claims on TikTok: what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1 weight loss claims on TikTok: what the data says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator discontinued semaglutide after approximately 45 to 50 pounds of weight loss and reports continued loss through the following 3 months, reaching 80 to 85 pounds total before becoming pregnant.
FormBlends verdict
The creator discontinued semaglutide after approximately 45 to 50 pounds of weight loss and reports continued loss through the following 3 months, reaching 80 to 85 pounds total before becoming pregnant. This trajectory is atypical compared to post-discontinuation data from the STEP 1 Extension trial, where participants regained roughly two-thirds of lost weight within one year of stopping the medication. Her subsequent pregnancy adds a significant confounding variable that makes this experience difficult to generalize.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator discontinued semaglutide after approximately 45 to 50 pounds of weight loss and reports continued loss through the following 3 months, reaching 80 to 85 pounds total before becoming pregnant. This trajectory is atypical compared to post-discontinuation data from the STEP 1 Extension trial, where participants regained roughly two-thirds of lost weight within one year of stopping the medication. Her subsequent pregnancy adds a significant confounding variable that makes this experience difficult to generalize.
- The STEP 1 Extension trial (Wilding et al., 2022) found participants regained approximately two-thirds of their weight within 12 months of stopping semaglutide.
- Continued weight loss after stopping a GLP-1 medication is possible but represents an outlier outcome relative to clinical trial data.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The STEP 1 Extension trial (Wilding et al., 2022) found participants regained approximately two-thirds of their weight within 12 months of stopping semaglutide.
- Continued weight loss after stopping a GLP-1 medication is possible but represents an outlier outcome relative to clinical trial data.
- Pregnancy significantly alters appetite, metabolism, and weight trajectory, making this video a poor comparison point for non-pregnant individuals considering stopping GLP-1 therapy.
- GLP-1 receptor agonists work by suppressing appetite through brain receptor activity. When the drug clears the body, that suppression diminishes regardless of how much weight was lost on it.
- Gaining 3 to 5 pounds during pregnancy is not a universally appropriate target. Recommended gestational weight gain varies by pre-pregnancy BMI per ACOG guidelines and should be discussed with an obstetric provider.
- The creator's caption caveat, that her experience may not apply to others, is scientifically accurate and important. The body of the video, seen without that caveat, risks creating a misleading impression for the 2.4 million viewers.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Aria | ON Food Creator 🇨🇦 · TikTok creator
2.4M views on this video
Replying to @Lizzie the truth behind my personal weight loss. This may not be the case for every individual! #weightloss #glp1forweightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Aria | ON Food Creator 🇨🇦, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.